References
- 1. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N. Engl. J. Med. 2017; 376: 2367-75.
- 2. Ertuğrul MB, Baktıroğlu S. Diabetic foot and osteomyelitis. J Klimik. 2005; 1: 8-13.
- 3. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America’s diabetic foot infection classification system. Clin Infect Dis. 2007; 44: 562-5.10.1086/51103617243061
- 4. Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med. 2018; 35: 78-88.10.1111/dme.13537576551229083500
- 5. IWGDF Guideline on the diagnosis and treatment of foot infection in persons with diabetes [https://iwgdfguidelines.org/wp-content/uploads/2019/05/05-IWGDF-infection-guideline-2019.pdf] (Elérve: 2020.09.23)
- 6. Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016; 353: 2089.10.1136/bmj.i208927365494
- 7. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924-6.10.1136/bmj.39489.470347.AD233526118436948
- 8. Senneville E, Abbas ZG, Aragón-Sánchez J, et al. Diagnosis of infection in the foot in diabetes: a systematic review. Diabetes Metabol Res Rev. 2019; 36: 3281.
- 9. Peters EJG, Senneville E, Abbas ZG, et al. Interventions in the management of infection in the foot in diabetes: a systematic review (update). Diabetes Metabol Res Rev. 2020; 36: 3282.10.1002/dmrr.328232176437
- 10. Uçkay I, Gariani K, Pataky Z, Lipsky BA. Diabetic foot infections: state-of-the-art. Diabetes Obes Metab. 2014; 16: 305-16.10.1111/dom.1219023911085
- 11. Rosskopf AB, Loupatatzis C, Pfirrmann CWA, Böni T, Berli MC. The Charcot foot: a pictorial review. Insights Imaging. 2019; 10: 77.10.1186/s13244-019-0768-9668284531385060
- 12. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54: 132-73.10.1093/cid/cis34622619242
- 13. Rajbhandari SM, Sutton M, Davies C, et al. ‚Sausage toe’: a reliable sign of underlying osteomyelitis. Diabet Med. 2000; 17: 74-7.10.1046/j.1464-5491.2000.00194.x10691164
- 14. Ertuğrul BM, Savk O, Öztürk B, Çobanoğlu M, Öncü S, Sakarya S. The diagnosis of diabetic foot osteomyelitis: examination findings and laboratory values. Med Sci Monit. 2009; 15: 307-12.
- 15. Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA. 1991; 266: 1246-51.10.1001/jama.1991.03470090080036
- 16. Tülek N, et al. A prospective, multi-center study: factors related to the management of diabetic foot infections. Eur J Clin Microbiol Infect Dis. 2012; 31: 2345-2352.10.1007/s10096-012-1574-1
- 17. Berendt AR, Peters EJ, Bakker K, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008; 24: 145-61.10.1002/dmrr.836
- 18. Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA. 2008; 299: 806-13.
- 19. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet. 2005;366: 1725-35.10.1016/S0140-6736(05)67699-4
- 20. Gajdács M, Spengler G, Urbán E. Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik’s Cube of Clinical Microbiology? Antibiotics 2017; 6: 25.
- 21. Lipsky BA, Peters EJ, Senneville E, et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev. 2012; 28: 163-78.10.1002/dmrr.224822271739
- 22. Ertuğrul MB, Baktıroğlu S, Aksoy M, Çalangu S. Diabetic foot and infection. J Klimik. 2004;17: 3-12.
- 23. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997; 25: 1318-1326.10.1086/5161489431370
- 24. Lipsky BA. Bone of contention: diagnosing diabetic foot osteomyelitis. Clin Infect Dis. 2008; 47: 528-30.10.1086/59001218611161
- 25. Lipsky BA. Diagnosing and Treating Diabetic Foot Infections. Klimik Derg. 2009; 22: 2-13.
- 26. Lam K, van Asten SA, Nguyen T, La Fontaine J, Lavery LA. Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review. Clin Infect Dis. 2016;63: 944-8.10.1093/cid/ciw44527369321
- 27. Uzun G, Solmazgül E, Çürüksulu H, et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med. 2007; 213: 305-12.10.1620/tjem.213.30518075234
- 28. Ertuğrul MB. Diabetic foot infections. Türkiye Klinikleri J Gen Surg-Special Topics. 2010; 3: 46-56.
- 29. Van Asten SA, Jupiter DC, Mithani M, La Fontaine J, Davis KE, Lavery LA. Erythrocyte sedimentation rate and C- reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. Int Wound J. 2017;14: 142-8.10.1111/iwj.12574795014426953894
- 30. Jeffcoate WJ, Lipsy BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis. 2004; 39: 115-22.10.1086/38327215306989
- 31. Beaman FD, Wessell DE, Cassidy RC, et al. ACR Appropriateness Criteria® Suspected Osteomyelitis of the Foot in Patients with Diabetes Mellitus. Expert Panel on Musculoskeletal Imaging. J Am Coll Radiol. 2019; 16: 440-50.
- 32. Llewellyn A, Jones-Diette J, Kraft J, Holton C, Harden M, Simmonds M. Imaging tests for the detection of osteomyelitis: a systematic review. Health Technol Assess. 2019;23: 1-128.10.3310/hta23610684311431670644
- 33. Ertuğrul MB, Baktiroğlu S, Salman S, et al. The diagnosis of osteomyelitis of the foot in diabetes: microbiological examination vs. magnetic resonance imaging and labelled leucocyte scanning. Diabet Med. 2006; 23: 649-53.10.1111/j.1464-5491.2006.01887.x16759307
- 34. Gariani K, Uçkay I, Lipsky BA. Managing diabetic foot infections: a review of the new guidelines. Acta Chir Belg. 2014; 114 :7-16.10.1080/00015458.2014.11680970
- 35. Glaudemans AW, Uçkay I, Lipsky BA. Challenges in diagnosing infection in the diabetic foot. Diabet Med. 2015; 32: 748-59.10.1111/dme.1275025765225
- 36. Al-Mayahi M, Cian A, Lipsky BA, et al. Administration of antibiotic agents before intraoperative sampling in orthopedic infections alters culture results. J Infect. 2015; 71: 518-25.10.1016/j.jinf.2015.08.00226283328
- 37. Jude EB, Selby PL, Mawer EB, et al. Inflammatory and bone turnover markers in Charcot arthropaty and osteomyelitis of the feet in diabetic patients (abstract). Diabetologia. 2002; 45: 341-2.
- 38. Çildağ MB, Ertuğrul BM, Köseoğlu OF, Çildağ S, Armstrong DG. Angiographic assessment of atherosclerotic load at the lower extremity in patients with diabetic foot and Charcot neuroarthropathy. J Chin Med Assoc. 2018; 81: 565-70.10.1016/j.jcma.2017.09.00629056486
- 39. Senneville E, Morant H, Descamps D, et al. Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients with diabetes and suspected osteomyelitis of the foot. Clin Infect Dis. 2009; 48: 888-93.10.1086/59726319228109
- 40. Nelson A, Wright-Hughes A, Backhouse MR, et al. CODIFI (Concordance in Diabetic Foot Ulcer Infection): a cross-sectional study of wound swab versus tissue sampling in infected diabetic foot ulcers in England. BMJ Open. 2018; 8: 019437.10.1136/bmjopen-2017-019437587972929391370
- 41. Gajdács M, Urbán E. The relevance of anaerobic bacteria in brain abscesses: a ten-year retrospective analysis (2008-2017). Infect Dis (Lond). 2019; 51: 779-781.10.1080/23744235.2019.164885731368384
- 42. Gajdács M, Urbán E. Relevance of anaerobic bacteremia in adult patients: A never-ending story? Eur. J. Microbiol. Immunol 2020; 10: 64-75.
- 43. Hatipoğlu M, Mutluoğlu M, Uzun G, Karabacak E, Turhan V, Lipsky BA. The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey. Eur J Clin Microbiol Infect Dis. 2014; 33: 871-8.10.1007/s10096-014-2047-524452966
- 44. Tumminello A, Dominguez D, Lebowitz D, et al. Staphylococcus aureus versus streptococci in orthopaedic infections. Infect Dis (Lond). 2017; 49: 716-8.10.1080/23744235.2017.131821928467136
- 45. Uçkay I, Pires D, Agostinho A, et al. Enterococci in orthopaedic infections: Who is at risk getting infected? J Infect. 2017; 75: 309-14.
- 46. Gariani K, Lebowitz D, von Dach E, Kressmann B, Lipsky BA, Uçkay I. Remission in diabetic foot infections: Duration of antibiotic therapy and other possible associated factors. Diabetes Obes Metab. 2019; 21: 244-51.10.1111/dom.1350730129109
- 47. Gajdács M. Epidemiology and resistance trends of Staphylococcus aureus isolated from vaginal samples: a 10-year retrospective study in Hungary. Acta Dermatovenerol Alp Pannonica Adriat. 2019; 28: 143-147.10.15570/actaapa.2019.35
- 48. Percival SL, Malone M, Mayer D, Salisbury AM, Schultz G. Role of anaerobes in polymicrobial communities and biofilms complicating diabetic foot ulcers. Int Wound J. 2018; 15: 776-82.10.1111/iwj.12926795014629863794
- 49. Charles PG, Uçkay I, Kressmann B, Emonet S, Lipsky BA. The role of anaerobes in diabetic foot infections. Anaerobe. 2015; 34: 8-13.10.1016/j.anaerobe.2015.03.00925841893
- 50. Uçkay I, Gariani K, Dubois-Ferrière V, Suvà D, Lipsky BA. Diabetic foot infections: recent literature and cornerstones of management. Curr Opin Infect Dis. 2016; 29: 145-52.10.1097/QCO.000000000000024326779774
- 51. Selva Olid A, Solà I, Barajas-Nava LA, Gianneo OD, Bonfill Cosp X, Lipsky BA. Systemic antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev. 2015; 9: CD009061.10.1002/14651858.CD009061.pub2850498826337865
- 52. Gajdács M, Burián K, Terhes G. Resistance Levels and Epidemiology of Non-Fermenting Gram-Negative Bacteria in Urinary Tract Infections of Inpatients and Outpatients (RENFUTI): A 10-Year Epidemiological Snapshot. Antibiotics 2019; 9: 143.10.3390/antibiotics8030143678425631505817
- 53. Lebowitz D, Gariani K, Kressmann B, et al. Are antibiotic-resistant pathogens more common in subsequent episodes of diabetic foot infection? Int J Infect Dis. 2017; 59: 61-4.
- 54. Uckay I, Berli M, Sendi P, Lipsky BA. Principles and practice of antibiotic stewardship in the management of diabetic foot infections. Curr Opin Infect Dis. 2019; 32: 95-101.10.1097/QCO.000000000000053030664029
- 55. CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. [https://www.cdc.gov/antibioticuse/healthcare/pdfs/hospital-core-elements-H.pdf] (Elérve: 2020.09.23)
- 56. Post V, Wahl P, Uçkay I, et al. Phenotypic and genotypic characterisation of Staphylococcus aureus causing musculoskeletal infections. Int J Med Microbiol. 2014; 304: 565-76.10.1016/j.ijmm.2014.03.00324768432
- 57. Zenelaj B, Bouvet C, Lipsky BA, Uçkay I. Do diabetic foot infections with methicillin-resistant Staphylococcus aureus differ from those with other pathogens? Int J Low Extrem Wounds. 2014; 13: 263-72.
- 58. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother. 2006; 50: 2875-9.10.1128/AAC.00286-06153869316870792
- 59. Gajdács M, Albericio F. Antibiotic Resistance: From the Bench to Patients. Antibiotics 2019; 8: 129.10.3390/antibiotics8030129678386831461842
- 60. Malik A, Mohammad Z, Ahmad J. The diabetic foot infections: biofilms and antimicrobial resistance. Diabetes Metab Syndr. 2013; 7: 101-7.10.1016/j.dsx.2013.02.00623680250
- 61. Vatan A, Saltoğlu N, Yemisen L, et al. Association between biofilm and multi/extensive drug resistance in diabetic foot infection. Int J Clin Pract. 2018; 72: e13060.10.1111/ijcp.1306029381248
- 62. Johani K, Fritz BG, Bjarnsholt T, et al. Understanding the microbiome of diabetic foot osteomyelitis: insights from molecular and microscopic approaches. Clin Microbiol Infect. 2019; 25: 332-9.10.1016/j.cmi.2018.04.03629787888
- 63. Wilson BM, Bessesen MT, Doros G, et al. Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration. JAMA Netw Open. 2019; 2: 1916003.10.1001/jamanetworkopen.2019.16003690281431755948
- 64. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampicinofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother. 2001; 48: 927-30.10.1093/jac/48.6.92711733482
- 65. Wilson BM, Bessesen MT, Doros G, Brown ST, Saade E, Hermos J, Perez F, Skalweit M, Spellberg B, Bonomo RA. Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration. JAMA Netw Open 2019; 2: e1916003.10.1001/jamanetworkopen.2019.16003
- 66. Lipsky BA. Treating diabetic foot osteomyelitis primarily with surgery or antibiotics: have we answered the question? Diabetes Care. 2014; 37: 593-5.
- 67. Kosinski MA, Lipsky BA. Current medical management of diabetic foot infections. Expert Rev Anti-Infect Ther 2010; 8: 1293-1305.10.1586/eri.10.12221073293
- 68. Lazaro-Martinez JL, Aragon-Sanchez J, Garcia-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care. 2014; 37: 789-95.10.2337/dc13-152624130347
- 69. Matthews PC, Berendt AR, Lipsky BA. Clinical management of diabetic foot infection: diagnostics, therapeutics and the future. Expert Rev Anti-Infect Ther 2007; 5: 117-127.10.1586/14787210.5.1.11717266459
- 70. Tone A, Nguyen S, Devemy F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: A multicenter open label controlled randomized study. Diabetes Care. 2015; 38: 302-7.10.2337/dc14-151425414157
- 71. Waibel F, Berli M, Catanzaro S, et al. Optimization of the antibiotic management of diabetic foot infections: protocol for two randomized-controlled trials. Trials. 2020; 21: 54.10.1186/s13063-019-4006-z695086731915048
- 72. Shiraev TP, Lipsky BA, Kwok TMY, Robinson DA. Utility of Culturing Marginal Bone in Patients Undergoing Lower Limb Amputation for Infection. J Foot Ankle Surg. 2019; 58: 847-51.10.1053/j.jfas.2018.12.01231345756
- 73. Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2017; 6: CD011038.10.1002/14651858.CD011038.pub2648188628613416
- 74. Uçkay I, Kressmann B, Di Tommaso S, et al. A randomized controlled trial of the safety and efficacy of a topical gentamicin-collagen sponge in diabetic patients with a mild foot ulcer infection. SAGE Open Med. 2018; 6: 2050312118773950.10.1177/2050312118773950595457429785265
- 75. Uçkay I, Kressmann B, Malacarne S, et al. A randomized, controlled study to investigate the efficacy and safety of a topical gentamicin-collagen sponge in combination with systemic antibiotic therapy in diabetic patients with a moderate or severe foot ulcer infection. BMC Infect Dis. 2018; 18: 361.10.1186/s12879-018-3253-z609084730068306